Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.

Literature DB >> 15318682

Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.

Stewart B Harris¹, Cynthia N Lank.

Abstract

Entities: Disease

Mesh：

Substances：
Hypoglycemic Agents

Year: 2004 PMID： 15318682 PMCID： PMC2214567

Source DB: PubMed Journal: Can Fam Physician ISSN： 0008-350X Impact factor: 3.275

× No keyword cloud information.

20 in total

1. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors: I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal: BMJ Date: 2000-08-12

3. The use of population attributable risk to estimate the impact of prevention and early detection of type 2 diabetes on population-wide mortality risk in US males.

Authors: K M Narayan; T J Thompson; J P Boyle; G L Beckles; M M Engelgau; F Vinicor; D F Williamson
Journal: Health Care Manag Sci Date: 1999-12

4. Projected impact of implementing the results of the diabetes prevention program in the U.S. population.

Authors: Sharon H Saydah; Danita Byrd-Holt; Maureen I Harris
Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112

5. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices.

Authors: L A Leiter; A Barr; A Bélanger; S Lubin; S A Ross; H D Tildesley; N Fontaine
Journal: Diabetes Care Date: 2001-06 Impact factor: 19.112

Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.

1. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

3. The use of population attributable risk to estimate the impact of prevention and early detection of type 2 diabetes on population-wide mortality risk in US males.

4. Projected impact of implementing the results of the diabetes prevention program in the U.S. population.

5. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices.

6. Secular trends in the body mass index of Canadian children.

7. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

8. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

9. Type 2 diabetes in family practice. Room for improvement.

10. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

1. Practice tips. Improving hypertension management in my practice.

Review 2. Risk factors preceding type 2 diabetes and cardiomyopathy.

3. Cardioprotective medication use in hemodialysis patients.

Review 4. Management of type 2 diabetes mellitus. Role of thiazolidinediones.

5. Comorbidity and glycemia control among patients with type 2 diabetes in primary care.

Review 6. Hemoglobin A1c: past, present and future.